Search results for "Sodium"

showing 10 items of 1605 documents

COVID-19 and diabetes management: What should be considered?

2020

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Clinical effectivenessbusiness.industryEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cardiovascular disease COVID-19 Diabetes DPP4 GLP-1RA Hydroxychloroquine Pioglitazone SGLT-2General Medicinemedicine.diseaseEndocrinologyDiabetes managementDiabetes mellitusInternal MedicinemedicineSodium-Glucose Cotransporter 2 InhibitorIntensive care medicinebusinessPioglitazonemedicine.drugDiabetes research and clinical practice
researchProduct

Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune di…

2015

Bernhard Manger,1 Falk Hiepe,2 Matthias Schneider,3 Margitta Worm,4 Peter Wimmer,5 Eva-Maria Paulus,5 Andreas Schwarting6 1University Hospital Erlangen, Med Clinic III Polyclinic, Erlangen, 2Rheumatology, University Hospital Charité, Campus Mitte, Berlin, 3Policlinic of Rheumatology, Heinrich-Heine-Universität, Düsseldorf, 4Department of Dermatology, Venereology and Allergology, University Hospital Charité, Campus Mitte, Berlin, 5Novartis Pharma GmbH, Nürnberg, 6Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany Background: The purpose of this study was to assess changes in gastrointestinal symptom severity in pati…

medicine.medical_specialtyAbdominal painClinical and Experimental GastroenterologyNauseabusiness.industrymycophenolate mofetilGastroenterologyautoimmune diseaseenteric-coated mycophenolate sodiumpatient-reported outcomeIndigestionhealth-related quality of lifeQuality of lifeRating scaleInternal medicineClinical endpointmedicinePatient-reported outcomemedicine.symptomAdverse effectbusinessOriginal ResearchClinical and Experimental Gastroenterology
researchProduct

Stimulation with carbachol alters endomembrane distribution and plasma membrane expression of intracellular proteins in lacrimal acinar cells.

2000

The events that lead to Sjogren's autoimmune processes in the lacrimal gland remain poorly understood. The acinar cell's responses to acute cholinergic stimulation include release of secretory products across the apical plasma membrane (apm) and a number of processes related to traffic between endomembrane compartments and the basal-lateral plasma membranes (blm), such as recruitment of Na, K-ATPase, accelerated recycling, and accelerated transcytosis of secretory IgA. We tested the hypothesis that stimulation-induced acceleration of endomembrane traffic is accompanied by changes in compartmentation and increased blm expression of proteins that are normally sequestered in endomembrane compa…

medicine.medical_specialtyAcid PhosphataseImmunoblottingGolgi ApparatusStimulationBiologyCholinergic AgonistsCathepsin BCathepsin BCellular and Molecular Neurosciencesymbols.namesakeInternal medicinemedicineAcinar cellAnimalsEndomembrane systemCells Culturedrab5 GTP-Binding ProteinsDifferential centrifugationEnzyme PrecursorsCell MembraneHistocompatibility Antigens Class IIMembrane Proteinsalpha-GlucosidasesGolgi apparatusGalactosyltransferasesCathepsinsSensory SystemsStimulation Chemicalbeta-N-AcetylhexosaminidasesCell biologyOphthalmologyEndocrinologySjogren's SyndromeTranscytosisrab GTP-Binding ProteinssymbolsCarbacholElectrophoresis Polyacrylamide GelFemaleRabbitsSodium-Potassium-Exchanging ATPaseIntracellularExperimental eye research
researchProduct

Effect of sodium bicarbonate and beta-alanine supplementation on maximal sprint swimming

2013

Background. This study examined the effect of simultaneous supplementation of extracellular buffer sodium bicarbonate (SB) and intracellular buffer beta-alanine (BA) on maximal sprint swimming. Methods. Thirteen competitive male swimmers completed 4 different treatments (placebo [PL], SB, BA + PL, and BA + SB) in a crossover procedure. PL or SB supplementation (0.3 g/kg body weight) was ingested 60 min before two maximal 100-m freestyle swims that were performed with a passive recovery of 12-min between each swim. Because of the known long washout period for carnosine, four weeks of BA supplementation (4.8 g per day) was started after the first week of PL or SB supplementation and performan…

medicine.medical_specialtyAlkalosisPassive recoverybeta-AlanineCarnosineErgogenic aidergogenic aidchemistry.chemical_compoundAnimal sciencemedicineBlood lactatealkaloosiSodium bicarbonateNutrition and Dieteticsbusiness.industryanaerobinen kuormitusergogeeninen apukeinoAlkalosismedicine.diseaseanaerobic exercisechemistrySprintAnaerobic exercisePhysical therapyalkalosisbufferbusinessAnaerobic exercisehuman activitiesBufferpuskuriResearch ArticleFood ScienceJournal of the International Society of Sports Nutrition
researchProduct

Future perspectives of the pharmacological management of diabetic dyslipidemia

2019

Introduction: Diabetic dyslipidemia is frequent among patients with type 2 diabetes mellitus (T2DM) and is characterized by an increase in triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and small-dense (atherogenic) particles, and by a decrease in low high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 that are strongly related to insulin resistance. The increased flux of free fatty acids from adipose tissue to the liver aggravates hepatic insulin resistance and promotes all of aspects of the dyslipidemic state. Areas covered: Statins are the first-line agents for treatment while other lipid-lowering drugs (ezetimibe, fibrate and proprotein convertase…

medicine.medical_specialtyApolipoprotein Bmedicine.drug_classglucagon like peptide-1 receptor agonist (GLP-1RA)Fibrate030226 pharmacology & pharmacystatins03 medical and health sciences0302 clinical medicineInsulin resistanceEzetimibeInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsOmega 3 fatty acidDyslipidemiasHypolipidemic Agentsfibratebiologybusiness.industrydyslipidemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineLipidmedicine.diseasesodium/glucose cotransporter 2 inhibitors (SGLT-2is)LipidsEndocrinologyDiabetes Mellitus Type 2Cardiovascular Diseases030220 oncology & carcinogenesisDipeptidyl peptidase-4 inhibitors (DPP-4is)Dietary Supplementsbiology.proteinKexinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistancebusinessDyslipidemiamedicine.drugezetimibeproprotein convertase subtilisin/kexin type 9 (PCSK9)
researchProduct

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

2021

Abstract Aims  Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin–angiotensin–aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain. Methods and results  The CREDENCE trial randomized 4401 participants with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo. In this post hoc analysis using an intention-to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to eith…

medicine.medical_specialtyCardiac & Cardiovascular SystemsINHIBITIONRATIONALEPlaceboHYPERKALEMIAMECHANISMSHyperkalaemiaChronic kidney diseaseInternal medicineDiabetes mellitusType 2 diabetes mellitusEND-POINTSPost-hoc analysismedicineHumansCanagliflozinRenal Insufficiency Chronic1102 Cardiorespiratory Medicine and HaematologySodium-Glucose Transporter 2 InhibitorsCanagliflozinOUTCOMESScience & Technologybusiness.industryType 2 Diabetes Mellitus1103 Clinical Sciencesmedicine.diseaseCardiovascular System & HematologyDiabetes Mellitus Type 2Serum potassiumCardiovascular System & CardiologyPotassiumCardiology and Cardiovascular MedicinebusinessComplicationLife Sciences & BiomedicineSGLT2 inhibitorsKidney diseasemedicine.drugEuropean Heart Journal
researchProduct

Uniform response of c-raf expression to differentiation induction and inhibition of proliferation in a rat rhabdomyosarcoma cell line

1990

The clonal rat rhabdomyosarcoma cell line BA-HAN-1C is composed of proliferating mononuclear cells, some of which spontaneously fuse to terminally differentiated myotube-like giant cells. Both the induction of differentiation by retinoic acid (RA) and by sodium butyrate (NaBut), as well as the inhibition of proliferation by fetal calf serum (FCS)-depleted medium uniformly resulted in the same effects. There was a significant (p less than 0.001) inhibition of proliferation and induction of cellular differentiation, as evidenced by a significant (p less than 0.05) increase in creatine kinase activity. Furthermore, after exposure to RA-supplemented or FCS-depleted medium, a significant (p less…

medicine.medical_specialtyCellular differentiationRetinoic acidTretinoinBiologyPeripheral blood mononuclear cellCell Fusionchemistry.chemical_compoundInternal medicineProto-OncogenesRhabdomyosarcomaTumor Cells CulturedmedicineAnimalsRNA MessengerRNA Neoplasmc-RafCreatine KinaseMessenger RNACell DifferentiationSodium butyrateBlotting NorthernMolecular biologyRatsGene Expression Regulation NeoplasticButyratesMicroscopy ElectronEndocrinologychemistryGiant cellCell cultureButyric AcidCell DivisionVirchows Archiv B Cell Pathology Including Molecular Pathology
researchProduct

Effects of Sodium dependent Glucose Transporter 2 (SGLT2) Inhibition with Empagliflozin on Oxidative Stress and Endothelial Dysfunction in STZ-Induce…

2013

medicine.medical_specialtyChemistryDiabetic ratmedicine.diseasemedicine.disease_causeBiochemistryEndocrinologyGLUCOSE TRANSPORTER 2Physiology (medical)Internal medicinemedicineEmpagliflozinEndothelial dysfunctionSodium dependentOxidative stressFree Radical Biology and Medicine
researchProduct

Angiotensin II-Stoffwechsel bei Angiotensininfusion und bei Kochsalzentzug

1975

1. Bei funf normotonen Probanden wurde im arteriellen und venosen Plasma des Unterarms vor und nach diatetischem Salzentzug sowie vor und wahrend Infusion von Angiotensin II-amid Angiotensin II (A II) und der Angiotensinmetabolit Angiotensin (3–8)-Hexapeptid (H) nach dunnschichtchromatographischer Trennung radioimmunologisch bestimmt.

medicine.medical_specialtyChemistryRadioimmunoassayGeneral MedicineMetabolismMolecular medicineAngiotensin IIEndocrinologyInternal medicineDrug DiscoveryRenin–angiotensin systemmedicineMolecular MedicineGenetics (clinical)SODIUM DEPLETIONKlinische Wochenschrift
researchProduct

Chloride/sodium ratio and sodium.chloride difference inpatients with renal failure and metabolic acidosis in hemodialysis treatment

2018

medicine.medical_specialtyChloride sodiumbusiness.industrySodiummedicine.medical_treatmentClinical Biochemistrychemistry.chemical_elementMetabolic acidosismedicine.diseaseBiochemistryInorganic ChemistryEndocrinologychemistryInternal medicinemedicinemetabolic acidosis chloirde/sodium ratio sodium-chloride difference Stewart's methodIn patientHemodialysisbusiness
researchProduct